Share this article
Share this article
ResearchAndMarkets.com s offering.
Growing pharmaceutical industry, increasing uptake of multifunctional excipients, and the availability of high quality raw materials and excipients are the key driving factors of the market. Furthermore, increasing chronic disease prevalence around the world enhances the demand for pharmaceutical products and thereby excipients.
Market Segmentation
Recent Developments
2020: Evonik launched RESOMER Precise platform of custom functional excipients to precisely control the release profile of parenteral drug products.
In April 2019, Colorcon, Inc. (US) signed an agreement with DuPont Nutrition and Biosciences (US) in order to enhance the current product portfolio of CR Alliance products.
iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), ARCA biopharma, Inc (NASDAQ:ABIO) - The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme s Clinical Trial Setback, 2 IPOs
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABBV) - The Daily Biotech Pulse: Merck s Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: Matthew Foster, MD, and his UNC Lineberger colleagues have used an experimental safety switch incorporated as part of a chimeric antigen receptor-modified T cell therapy (CAR-T) for an aggressive form. view more
Credit: UNC Lineberger Comprehensive Cancer Center
CHAPEL HILL, North Carolina UNC Lineberger Comprehensive Cancer Center researchers have successfully used an experimental safety switch, incorporated as part of a chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy, to reduce the severity of treatment side effects that sometimes occur. This advance was seen in a patient enrolled in a clinical trial using CAR-T to treat refractory acute B-cell leukemia. It demonstrates a proof-of-principle for possible expanded use of CAR-T immunotherapy paired with the safety switch.